Venus Concept Announces Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Revenue Guidance
Fourth Quarter 2022 Summary & Recent Highlights:
- Total revenue of
$24.3 million , down$8.3 million , or 26%, year-over-year; up$2.7 million , or 13% quarter-over-quarter.U.S. revenue down 14% year-over-year; up 17% quarter-over-quarter.- Cash system revenue represented approximately 71% of total systems and subscriptions revenue, compared to 60% in the prior year period.
- GAAP net loss attributable to stockholders of
$9.9 million , compared to GAAP net loss attributable to stockholders of$4.3 million last year. - Adjusted EBITDA loss of
$6.3 million , compared to Adjusted EBITDA loss of$2.5 million last year. - On
November 18, 2022 , the Company announced that completed a non-brokered private placement of convertible preferred stock and common stock of the Company. Pursuant to the Private Placement, an aggregate of 3,185,000 Preferred Shares and 1,750,000 Common Shares were issued, resulting in aggregate gross proceeds to the Company of$6.72 million before offering expenses. - On
December 21, 2022 , the Company announced receipt of a 510(k) clearance from theU.S. Food and Drug Administration (“FDA”) to market its AI.ME next generation robotic technology for fractional skin resurfacing. - On
February 3, 2023 , the Company announced a restructuring plan to reduce the Company’s cost structure and improve its operational efficiency and reported preliminary revenue results for the three months and twelve months endedDecember 31, 2022 . The Company expects the restructuring plan to result in total annual pre-tax savings of$13 million to$15 million beginning in 2024. - On
March 20, 2023 , the Company announced the launch of its latest generation of ARTAS iX, which is now broadly available to physicians specializing in hair transplantation worldwide. The latest generation of ARTAS iX sets a new standard for hair transplantation by leveraging cutting-edge robotics, machine vision, artificial intelligence, and machine learning technologies.
Management Commentary:
“As previously reported, our fourth quarter revenue results were consistent with the Company’s expectations and reflect a continued successful shift to prioritize cash system sales, which represented approximately 71% of total systems and subscriptions revenue, compared to 60% in the prior year period,” said
Fourth Quarter and Twelve Months of 2022 Revenue by Region and by Product Type:
Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||
(dollars in thousands) | (dollars in thousands) | |||||||||||||||||||||||
Revenues by region: | ||||||||||||||||||||||||
$ | 13,782 | $ | 16,055 | $ | 52,101 | $ | 51,400 | |||||||||||||||||
International | 10,504 | 16,579 | 47,396 | 54,222 | ||||||||||||||||||||
Total revenue | $ | 24,286 | $ | 32,634 | $ | 99,497 | $ | 105,622 | ||||||||||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||||||||||
(dollars in thousands) | (dollars in thousands) | |||||||||||||||||||||||
Revenues by product: | ||||||||||||||||||||||||
Subscription—Systems | $ | 5,777 | $ | 11,135 | $ | 35,267 | $ | 45,094 | ||||||||||||||||
Products—Systems | 14,068 | 16,580 | 47,906 | 43,106 | ||||||||||||||||||||
Products—Other (1) | 3,614 | 3,901 | 13,316 | 13,230 | ||||||||||||||||||||
Services (2) | 827 | 1,018 | 3,008 | 4,192 | ||||||||||||||||||||
Total revenue | $ | 24,286 | $ | 32,634 | $ | 99,497 | $ | 105,622 |
(1 | ) | Products-Other include ARTAS procedure kits, Viva tips and other consumables. |
(2 | ) | Services include extended warranty sales and VeroGrafters technician services. VeroGrafters technician services were discontinued in the fourth quarter of 2021. |
Fourth Quarter 2022 Financial Results:
Three Months Ended |
||||||||||||||||||||||||
2022 | 2021 | Change | ||||||||||||||||||||||
(in thousands, except percentages) | $ | % of Total | $ | % of Total | $ | % | ||||||||||||||||||
Revenues: | ||||||||||||||||||||||||
Subscription—Systems | $ | 5,777 | 23.8 | $ | 11,135 | 34.1 | $ | (5,357 | ) | (48.1 | ) | |||||||||||||
Products—Systems | 14,068 | 57.9 | 16,580 | 50.8 | (2,512 | ) | (15.2 | ) | ||||||||||||||||
Products—Other | 3,614 | 14.9 | 3,900 | 12.0 | (286 | ) | (7.3 | ) | ||||||||||||||||
Services | 827 | 3.4 | 1,018 | 3.1 | (191 | ) | (18.8 | ) | ||||||||||||||||
Total | $ | 24,286 | 100.0 | $ | 32,634 | 100.0 | $ | (8,347 | ) | (25.6 | ) |
Total revenue for the fourth quarter of 2022 decreased
Gross profit for the fourth quarter of 2022 decreased
Operating expenses for the fourth quarter of 2022 decreased
Operating loss for the fourth quarter of 2022 was
Net loss attributable to stockholders for the fourth quarter of 2022 was
As of
Fiscal Year 2022 Financial Results:
Twelve Months Ended |
||||||||||||||||||||||||
2022 | 2021 | Change | ||||||||||||||||||||||
(in thousands, except percentages) | $ | % of Total | $ | % of Total | $ | % | ||||||||||||||||||
Revenues: | ||||||||||||||||||||||||
Subscription—Systems | $ | 35,267 | 35.4 | $ | 45,094 | 42.7 | $ | (9,827 | ) | (21.8 | ) | |||||||||||||
Products—Systems | 47,906 | 48.1 | 43,106 | 40.8 | 4,800 | 11.1 | ||||||||||||||||||
Products—Other | 13,316 | 13.4 | 13,230 | 12.5 | 86 | 0.7 | ||||||||||||||||||
Services | 3,008 | 3.0 | 4,192 | 4.0 | (1,184 | ) | (28.3 | ) | ||||||||||||||||
Total | $ | 99,497 | 100.0 | $ | 105,622 | 100.0 | $ | (6,125 | ) | (5.8 | ) |
Total revenue for the twelve months ended
Net loss attributable to stockholders for the twelve months ended
Fiscal Year 2023 Revenue Guidance:
The Company expects total revenue for the twelve months ending
Conference Call Details:
Management will host a conference call at
For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13736286. The webcast will be archived at ir.venusconcept.com.
About
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements about our financial performance and metrics; the growth in demand for our systems and other products and sustainability thereof; and the efficacy of the restructuring plan, workforce reduction and management transition. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, general economic conditions and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements and those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended
Condensed Consolidated Balance Sheets
(In thousands of
Year Ended, |
||||||||
2022 | 2021 | |||||||
ASSETS | ||||||||
CURRENT ASSETS: | ||||||||
Cash and cash equivalents | $ | 11,569 | $ | 30,876 | ||||
Accounts receivable, net of allowance of |
37,262 | 46,918 | ||||||
Inventories | 23,906 | 20,543 | ||||||
Prepaid expenses | 1,688 | 2,737 | ||||||
Advances to suppliers | 5,881 | 5,667 | ||||||
Other current assets | 3,702 | 3,758 | ||||||
Total current assets | 84,008 | 110,499 | ||||||
LONG-TERM ASSETS: | ||||||||
Long-term receivables | 20,044 | 27,710 | ||||||
Deferred tax assets | 947 | 284 | ||||||
Severance pay funds | 741 | 817 | ||||||
Property and equipment, net | 1,857 | 2,669 | ||||||
Operating right-of-use assets, net | 5,862 | — | ||||||
Intangible assets | 11,919 | 15,393 | ||||||
Total long-term assets | 41,370 | 46,873 | ||||||
TOTAL ASSETS | $ | 125,378 | $ | 157,372 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Trade payables | $ | 8,033 | $ | 8,418 | ||||
Accrued expenses and other current liabilities | 16,667 | 19,512 | ||||||
Current portion of long-term debt | 7,735 | — | ||||||
Income taxes payable | 117 | 294 | ||||||
Unearned interest income | 2,397 | 2,678 | ||||||
Warranty accrual | 1,074 | 1,245 | ||||||
Deferred revenues | 1,765 | 2,030 | ||||||
Operating lease liabilities | 1,807 | — | ||||||
Current portion of government assistance loans | — | 543 | ||||||
Total current liabilities | 39,595 | 34,720 | ||||||
LONG-TERM LIABILITIES: | ||||||||
Long-term debt | 70,003 | 77,325 | ||||||
Income tax payable | 374 | 563 | ||||||
Accrued severance pay | 867 | 911 | ||||||
Deferred tax liabilities | — | 46 | ||||||
Unearned interest income | 957 | 1,355 | ||||||
Warranty accrual | 408 | 508 | ||||||
Long-term operating lease liabilities | 4,221 | — | ||||||
Other long-term liabilities | 215 | 348 | ||||||
Total long-term liabilities | 77,045 | 81,056 | ||||||
TOTAL LIABILITIES | 116,640 | 115,776 | ||||||
Commitments and Contingencies (Note 9) | ||||||||
STOCKHOLDERS’ EQUITY (Note 1): | ||||||||
Common Stock, |
29 | 27 | ||||||
Additional paid-in capital | 232,169 | 221,321 | ||||||
Accumulated deficit | (224,105 | ) | (180,405 | ) | ||||
TOTAL STOCKHOLDERS’ EQUITY | 8,093 | 40,943 | ||||||
Non-controlling interests | 645 | 653 | ||||||
8,738 | 41,596 | |||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 125,378 | $ | 157,372 |
The accompanying notes are an integral part of these consolidated financial statements.
Condensed Consolidated Statements of Operations
(In thousands of
Three Months Ended |
Twelve Months Ended |
||||||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||||||
(unaudited) | (unaudited) | ||||||||||||||||||
Revenue | |||||||||||||||||||
Leases | $ | 5,777 | $ | 11,316 | $ | 35,267 | $ | 45,094 | |||||||||||
Products and services | 18,509 | 21,498 | 64,230 | 60,528 | |||||||||||||||
24,286 | 32,634 | 99,497 | 105,622 | ||||||||||||||||
Cost of goods sold | |||||||||||||||||||
Leases | 1,366 | 3,015 | 9,435 | 10,459 | |||||||||||||||
Products and services | 7,131 | 6,782 | 24,091 | 21,069 | |||||||||||||||
8,497 | 9,797 | 33,526 | 31,528 | ||||||||||||||||
Gross profit | 15,789 | 22,837 | 65,971 | 74,094 | |||||||||||||||
Operating expenses: | |||||||||||||||||||
Selling and marketing | 9,300 | 11,951 | 40,276 | 41,290 | |||||||||||||||
General and administrative | 12,804 | 12,301 | 49,618 | 40,070 | |||||||||||||||
Research and development | 2,573 | 2,653 | 10,953 | 9,646 | |||||||||||||||
Gain on forgiveness of government assistance loans | — | — | (2,775 | ) | |||||||||||||||
Total operating expenses | 24,678 | 26,905 | 100,847 | 88,861 | |||||||||||||||
Loss from operations | (8,889 | ) | (4,068 | ) | (34,876 | ) | (14,767 | ) | |||||||||||
Other expenses: | |||||||||||||||||||
Foreign exchange loss (gain) | (1,002 | ) | 70 | 3,387 | 2,559 | ||||||||||||||
Finance expenses | 1,385 | 909 | 4,561 | 4,955 | |||||||||||||||
Loss on disposal of subsidiaries | 1,482 | 379 | 1,482 | 567 | |||||||||||||||
Loss before income taxes | (10,754 | ) | (5,426 | ) | (44,306 | ) | (22,848 | ) | |||||||||||
Income tax (benefit) expense | (814 | ) | (1,316 | ) | (722 | ) | (707 | ) | |||||||||||
Net loss | (9,940 | ) | (4,110 | ) | (43,584 | ) | (22,141 | ) | |||||||||||
Loss attributable to stockholders of the Company | (9,917 | ) | (4,333 | ) | (43,700 | ) | (23,013 | ) | |||||||||||
Income (loss) attributable to non-controlling interest | 23 | 223 | 116 | 872 | |||||||||||||||
Net loss per share: | |||||||||||||||||||
Basic | $ | (0.14 | ) | $ | (0.08 | ) | $ | (0.66 | ) | $ | (0.42 | ) | |||||||
Diluted | $ | (0.14 | ) | $ | (0.08 | ) | $ | (0.66 | ) | $ | (0.42 | ) | |||||||
Weighted-average number of shares used in per share calculation: | |||||||||||||||||||
Basic | 70,403 | 55,867 | 65,960 | 54,466 | |||||||||||||||
Diluted | 70,403 | 55,867 | 65,960 | 54,466 |
Condensed Consolidated Statements of Cash Flows
(in thousands)
Year Ended |
||||||||
2022 | 2021 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net loss | $ | (43,584 | ) | $ | (22,141 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 4,463 | 4,854 | ||||||
Stock-based compensation | 2,104 | 2,068 | ||||||
Provision (recovery) for bad debt | 7,337 | (263 | ) | |||||
Provision for inventory obsolescence | 2,420 | 1,456 | ||||||
Finance expenses and accretion | 414 | 1,779 | ||||||
Deferred tax recovery | (709 | ) | (165 | ) | ||||
Loss on sale of subsidiaries | — | 567 | ||||||
Loss on disposal of property and equipment | 158 | — | ||||||
Gain on forgiveness of government assistance loans | — | (2,775 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable short- and long-term | 9,855 | (869 | ) | |||||
Inventories | (5,783 | ) | (4,261 | ) | ||||
Prepaid expenses | 1,049 | (454 | ) | |||||
Advances to suppliers | (214 | ) | (3,080 | ) | ||||
Other current assets | 56 | 1,908 | ||||||
Operating right-of-use assets, net | (5,862 | ) | - | |||||
Other long-term assets | 200 | (98 | ) | |||||
Trade payables | (385 | ) | 2,096 | |||||
Accrued expenses and other current liabilities | (3,647 | ) | (889 | ) | ||||
Current operating lease liabilities | 1,807 | - | ||||||
Severance payments | 76 | (132 | ) | |||||
Unearned interest income | (679 | ) | 305 | |||||
Long-term operating lease liabilities | 4,221 | — | ||||||
Other long-term liabilities | (277 | ) | 323 | |||||
Net cash used in operating activities | (26,980 | ) | (19,771 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Purchases of property and equipment | (336 | ) | (512 | ) | ||||
Cash received from sale of subsidiaries, net of cash relinquished | - | (40 | ) | |||||
Net cash used in investing activities | (336 | ) | (552 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Exercises of 2020 December Public Offering Warrants | — | 903 | ||||||
2021 Private Placement, net of costs of |
— | 16,740 | ||||||
2022 Private Placement, net of costs of |
6,518 | — | ||||||
Proceeds from issuance of common stock | 2,135 | — | ||||||
Repayment of government assistance loans | (543 | ) | (738 | ) | ||||
Dividends from subsidiaries paid to non-controlling interest | (124 | ) | (293 | ) | ||||
Payment of earn-out liability | - | (147 | ) | |||||
Proceeds from exercise of options | 23 | 354 | ||||||
Net cash provided by financing activities | 8,009 | 16,819 | ||||||
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (19,307 | ) | (3,504 | ) | ||||
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of year | 30,876 | 34,380 | ||||||
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of year | $ | 11,569 | $ | 30,876 | ||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
Cash paid for income taxes | $ | 329 | $ | 116 | ||||
Cash paid for interest | $ | 4,189 | $ | 3,292 | ||||
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION: | ||||||||
Common stock issuance costs | $ | 438 | $ | - | ||||
2021 Private Placement costs | $ | - | $ | 259 | ||||
2022 Private Placement costs | $ | 202 | $ | - |
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as net income (loss) before foreign exchange loss (gain), financial expenses, income tax expense (benefit), depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under
We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the
The following reconciliation of net (loss) income to Adjusted EBITDA for the periods presented:
Reconciliation of Net loss to Non-GAAP Adjusted EBITDA
Three Months Ended December 31, | Year Ended, |
|||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Reconciliation of net loss to adjusted EBITDA | (in thousands) | (in thousands) | ||||||||||||||
Net loss | $ | (9,937 | ) | $ | (4,110 | ) | $ | (43,584 | ) | $ | (22,141 | ) | ||||
Foreign exchange loss | (1,002 | ) | 70 | 3,387 | 2,559 | |||||||||||
Loss on disposal of subsidiaries | 1,482 | 379 | 1,482 | 567 | ||||||||||||
Finance expenses | 1,385 | 909 | 4,561 | 4,955 | ||||||||||||
Income tax (benefit) expense | (816 | ) | (1,316 | ) | (722 | ) | (707 | ) | ||||||||
Depreciation and amortization | 1,170 | 1,099 | 4,463 | 4,854 | ||||||||||||
Stock-based compensation expense | 552 | 466 | 2,104 | 2,068 | ||||||||||||
Gain on forgiveness of government assistance loans | — | — | — | (2,775 | ) | |||||||||||
Inventory provision (1) | — | — | 1,388 | — | ||||||||||||
Other adjustments (2) | 819 | — | 1,544 | — | ||||||||||||
Adjusted EBITDA | $ | (6,347 | ) | $ | (2,503 | ) | $ | (25,377 | ) | $ | (10,620 | ) |
(1) For the year ended
(2) For the three and twelve months ended
Investor Relations Contact:ICR Westwicke on behalf ofVenus Concept :Mike Piccinino , CFA VenusConceptIR@westwicke.com
Source: Venus Concept Inc.